Free Publications

Search for cll returned 203 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

On World Cancer Day: LLS Honors International Researchers

World Cancer Day is February 4, when people across the globe come together to work toward reducing the global burden of cancer. An integral part of this work is scientific research that leads to innovative treatments, ultimately saving lives. Despite promising advances in treatment, cancers are among the leading cause of disease and deaths worldwide. Cancers know no boundaries, and have devastating impacts on families across the globe. In 2012, there were more than 900,000 new cases o ...

Read more

LLS Announces Recipients of Quest for Cures Grant Program

Contact: Andrea Greif
(914) 821-8958
andrea.greif@lls.org White Plains, NY (January 23, 2014) - The Leukemia & Lymphoma Society (LLS) today is pleased to announce the14 researchers who will receive funding through the Quest for Cures program - a new grant program that addresses three critical areas of blood cancer research. The three priority areas are: monitoring tumor cell heterogeneity and its contribution to response or resistance to therapy; molecular mecha ...

Read more

Cancer Research Funded by The Leukemia & Lymphoma Society Featured in New PBS Documentary Series


To view the entire multi-media release, click here. Contact: Marcie Klein
(914) 821-8205
marcie.klein@lls.org White Plains, NY (February 23, 2015) - Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nat ...

Read more

Kite Pharma and LLS Collaborate on CAR T-Cell Therapy for Lymphoma

Contact: Andrea Greif
(914) 821-8958 (p)
(914) 772-3027 (c)
andrea.greif@lls.org Santa Monica, Calif., and White Plains, NY: July 1, 2015 – Kite Pharma, Inc., KITE, +2.77% and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an inve ...

  • Photo
Read more

A Snowy Day in Atlanta to Commence #ASH17

The 59th ASH (American Society of Hematology) Annual Meeting & Exposition kicks off tomorrow here in Atlanta, drawing more than 25,000 researchers, physicians, biopharmaceutical company executives, patient advocates and industry experts from around the world to share the latest scientific clinical data in the blood cancers and other blood disorders. As we do each year, LLS opened the #ASH2017 weekend by hosting our own scientific symposium today, one day before the official start of ...

Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.